Trial announcement today . From what they have seen so far they...

Trial announcement today . From what they have seen so far they are on track for phase 2 in Australia and the USA .
Summary
• Solbec’s Board has met with the principal Investigator in its Phase I Clinical Trial
• The data generated to date shows no unexpected toxicity.
• Based on data generated to date Solbec’s Board is confident of progressing to Phase II
Clinical trials in patients with advanced cancer.
The Board of Director’s met recently with Professor Michael Millward, the principal investigator
in Solbec’s Phase I Trials of our lead compound SBP002 in Patients with advanced cancer. The
purpose of the meeting was to review the status of the trial.
The Phase I Trial is the first step in human testing of a new drug; this trial evaluates drug safety
and toxicity at different dose levels in a small number of volunteers The trial will also determine
the pharmacokinetics which is the action of drugs in the body, including the processes of
transformation, duration of action and elimination.
The data generated to date have shown no unexpected toxicity in the patients treated.
The principal investigator is continuing to enroll further patients in accordance with the Trial
Protocol.
The Board is satisfied with the results generated to date and is confident that the Trials will
provide sufficient data to enable Solbec to proceed with its applications in Australia and in the
United States for its Phase II Clinical Trials.